# INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

> **NCT04398433** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inovio Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Respiratory Papillomatosis

## Interventions

- **DRUG:** INO-3107
- **DEVICE:** CELLECTRA® 2000

## Key facts

- **NCT ID:** NCT04398433
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-07
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398433, "INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04398433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*